Stock Analysis
DexCom, Inc.DXCM
P/E 32.48×· 5Y range 24.35–269.17×· bottom 8% of history
Sector: Healthcare · Industry: Surgical & Medical Instruments & Apparatus
AnalystsStrong Buy36 analystsP/E 32.5× sits at the 8th percentile of its 5.086926762491444-year history.
Cash covers 139% of debt · Q2 2026.
PMP Verdict
Strong business, attractive price
Strengths
- Profitability95
- Financial Health93
High-quality business at an attractive price.
Bull Case
- ✓Piotroski F-Score 8/9 — high earnings quality
- ✓Altman Z 7.0 — safe-zone balance sheet
- ✓ROE 38.1% — efficient capital deployment
- ✓Revenue CAGR 17.5% — durable top-line growth
- ✓Interest coverage 16.7× — debt well covered
What's happening with DXCM
Profile
Strong profitability, financial health, earnings quality and growth.
How is each axis scored?
- Valuation54/100 · Moderate
- P/E vs own history (8th pct)25/25
- FCF yield (4.3%)12/25
- P/S (6.5x)12/25
- EV/EBIT (28.0x)5/25
- Growth82/100 · Strong
- Revenue CAGR (17.5%)20/25
- Net income CAGR (52.5%)25/25
- EPS CAGR 5Y (52.0%)25/25
- Fwd implied growth (8.7%)12/25
- Profitability95/100 · Strong
- ROIC (43.4%)25/25
- ROE (38.1%)25/25
- Net margin (20.1%)25/25
- Operating margin (22.9%)20/25
- Financial Health93/100 · Strong
- Altman Z (7.00)25/25
- Current ratio (1.73)18/25
- Interest coverage (16.7x)25/25
- Net cash / debt (Net cash)25/25
- Quality87/100 · Strong
- Piotroski F (8/9)25/25
- Beneish M (-2.84)25/25
- FCF conversion (141%)25/25
- Margin stability (σ 13.0%)12/25
- Moat56/100 · Moderate
- ROIC >12% years (3/8 yrs)6/25
- Median gross margin (64.5%)25/25
- FCF-positive years (10/10 yrs)25/25
- Worst-year net margin (worst -12.3%)0/25
Risk Flags
- ⚠3 loss-making years in recent history
About DexCom, Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. Show more
CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Headquarters: SAN DIEGO, CA · Employees: 11,100 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
54CP/E (TTM)32.4xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 24.4x–269.2x · 8th pct
P/FCF23.3xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield4.3%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.2%–6.3% · 91st pct
P/S (TTM)6.52xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 4.7x–28.0x · 17th pct
EV/EBIT28.0xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 21.8x–30.1x · 52nd pct
EV/Sales6.6xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E29.8xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio12.37xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.54B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC43.4%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE38.1%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA14.8%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin20.1%A
Grade A: HighNet Income / Revenue
Operating Margin22.9%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin62.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin28.3%A
Grade A: HighFCF / Revenue
True FCF Margin25.0%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
82ARevenue CAGR17.5%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR52.5%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)52.0%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth8.7%B
Grade B: LowAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-5.2%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income16.2%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue3.3%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
93A+Altman Z-Score7.00A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.73xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.40xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage16.7xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBITNet CashA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.53xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.39xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
87APiotroski F-Score8/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.84A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion140.5%A
Grade A: StrongFCF / Net Income
Margin Stability13.0%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue6.9%C
Grade C: AverageTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.74xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
AUGUSTINOS NICHOLAS Filed | AUGUSTINOS NICHOLAS | SellOpen market sale | -6539 | |
Brown Michael Jon Filed | Brown Michael Jon | SellOpen market sale | -1700 | |
AUGUSTINOS NICHOLAS Filed | AUGUSTINOS NICHOLAS | SellOpen market sale | -1550 | |
Sylvain Jereme M Filed | Sylvain Jereme M | SellOpen market sale | -3638 | |
Boehnlein Glenn S Filed | Boehnlein Glenn S | Grant / award | +5.8K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Stern Sadie Filed | Stern Sadie | SellOpen market sale | -2565 | |
Leach Jacob Steven Filed | Leach Jacob Steven | Tax withholding | -1451 | |
Sylvain Jereme M Filed | Sylvain Jereme M | Tax withholding | -1451 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
56CROIC >12% Years3/8 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)64.5%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years10/10 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-12.3%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$2.65
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$5.16
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.95
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.40B
Total debt obligations (short + long term)
Cash & Equiv.$1.95B
Cash and short-term investments
Net Debt$-548.60MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$2.62B
Shareholders' equity (book value)
Asset / Liability1.68xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$32.42B
Current Market Capitalization
Beta1.44C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 16, 2026
Key Insights: DexCom, Inc. (DXCM)
DXCM is down 1.90% at the last close. DexCom, Inc. meets 8 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 7.00 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.84 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 17% annually, with net income growing about 52% per year — a strong growth profile.
- DexCom, Inc. converts about 28% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- DexCom, Inc. posted a net loss in 3 of 10 available completed fiscal years (2016–2025).
- Return on equity of 38.1% is well above the market average.
See how DXCM ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all DXCM moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Pre-market | 86.19 | +3.26% | 2.46 |
| Oct 15 | Regular | 87.33 | +4.62% | 3.39 |
| Oct 15 | After-hours | 87.62 | +4.97% | 3.63 |
| Oct 6 | Regular | 83.02 | -4.46% | -4.04 |
| Oct 6 | After-hours | 83.75 | -3.62% | -3.29 |
Frequently Asked Questions about DXCM
What is the current DexCom, Inc. (DXCM) stock price?
DXCM is trading at $86.04 at the last market close, down 1.90% on the session. PreMarketPrice tracks DXCM pre-market, intraday and after-hours prices.
Is DXCM stock a buy right now?
PreMarketPrice's quantitative model rates DexCom, Inc.'s financial health at 93/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is DXCM stock overvalued?
DexCom, Inc. trades at a trailing P/E of 32.4 and our valuation score rates it 54/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does DexCom, Inc. report earnings?
No confirmed earnings date is currently scheduled for DXCM. The Earnings section lists recent reports and updates as dates are announced.
What sector does DexCom, Inc. operate in?
DexCom, Inc. operates in the Healthcare sector, within the Surgical & Medical Instruments & Apparatus industry. The Related Stocks section lists sector peers for comparison.
What does DexCom, Inc. do?
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients.
About DexCom, Inc. (DXCM) Stock
DexCom, Inc. (DXCM) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry. As of the latest update, DexCom, Inc. is trading at $86.04, down 1.90% on the day with a market capitalization of $32.4 billion. The financial health score for DXCM is 93/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for DXCM stock.
DXCM Stock Analysis & Key Metrics
On PreMarketPrice, you can track DexCom, Inc. (DXCM) across multiple dimensions:
- Pre-market price & movement: Real-time DXCM stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for DXCM with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for DexCom, Inc. across multiple reporting periods.
- Financial health score: A composite score of 93/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for DXCM.
- Sector peers: Compare DXCM against 6 other healthcare stocks on key financial metrics.
Is DXCM a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate DexCom, Inc. (DXCM) as an investment. The financial health score of 93/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.DexCom, Inc. (DXCM) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.